skip to Main Content

Frontline NALIRIFOX Regimen Demonstrates Promising Activity in Advanced PDAC

Frontline NALIRIFOX Regimen Demonstrates Promising Activity in Advanced PDAC
Promising disease control and survival was achieved with the use of liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) as a frontline treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase 1/2 trial.

Long-term follow-up results from the study were presented in a poster at the virtual 2020 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer meeting. Read more . . .


Back To Top